Oberlick E, Rees M, Seashore Ludlow B, Vazquez F, Nelson G, Dharia N, et al. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019;28:2331-2344.e8 pubmed publisher

Vieceli F, Bronner M. Leukocyte receptor tyrosine kinase interacts with secreted midkine to promote survival of migrating neural crest cells. Development. 2018;145: pubmed publisher

Infarinato N, Park J, Krytska K, Ryles H, Sano R, Szigety K, et al. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016;6:96-107 pubmed publisher

Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, et al. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2015;14:2433-40 pubmed publisher

Yamazaki S, Johnson T, Smith B. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. Drug Metab Dispos. 2015;43:1417-29 pubmed publisher

Peron M, Lovisa F, Poli E, Basso G, Bonvini P. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors. PLoS ONE. 2015;10:e0132330 pubmed publisher

Amin A, Rajan S, Liang W, Pongtornpipat P, Groysman M, Tapia E, et al. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. Cancer Res. 2015;75:2916-27 pubmed publisher

Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, et al. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. PLoS ONE. 2015;10:e0121378 pubmed publisher

Greenfield E, Griner E. Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. elife. 2014;3: pubmed publisher

Katayama R, Kobayashi Y, Friboulet L, Lockerman E, Koike S, Shaw A, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21:166-74 pubmed publisher

Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, et al. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int. 2014;2014:764981 pubmed publisher

Johnson T, Tan W, Goulet L, Smith E, Yamazaki S, Walker G, et al. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica. 2015;45:45-59 pubmed publisher

Korn R, Oklu R, Migdal C, Gotway M, Weiss G, Iafrate A, et al. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology. 2014;272:568-76 pubmed publisher

Fang J, Lee S. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility. Biochim Biophys Acta. 2014;1843:1285-94 pubmed publisher

Bonvini P, Zin A, Alaggio R, Pawel B, Bisogno G, Rosolen A. High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. Br J Cancer. 2013;109:3084-91 pubmed publisher

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis Model Mech. 2013;6:373-82 pubmed publisher

Tu W, Zhu C, Clark C, Christensen J, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 2010;10:556 pubmed publisher